Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTX NASDAQ:JANX NASDAQ:JBIO NASDAQ:TRDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$18.44+3.8%$16.74$6.21▼$24.27$939.56M0.781.51 million shs800,235 shsJANXJanux Therapeutics$15.33-2.5%$14.81$12.12▼$35.34$958.67M2.521.06 million shs550,012 shsJBIOJade Biosciences$20.08+2.3%$19.99$6.67▼$28.00$968.44M1.431.00 million shs684,572 shsTRDAEntrada Therapeutics$5.85-3.3%$6.79$4.93▼$16.45$234.87M-0.26438,722 shs566,335 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics+3.83%-4.80%+1.64%+32.47%+176.46%JANXJanux Therapeutics-2.48%-5.72%+4.71%+2.13%-42.06%JBIOJade Biosciences+2.34%-3.74%-8.31%-19.62%+130.54%TRDAEntrada Therapeutics-3.31%-15.09%-22.41%-53.68%-8.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$18.44+3.8%$16.74$6.21▼$24.27$939.56M0.781.51 million shs800,235 shsJANXJanux Therapeutics$15.33-2.5%$14.81$12.12▼$35.34$958.67M2.521.06 million shs550,012 shsJBIOJade Biosciences$20.08+2.3%$19.99$6.67▼$28.00$968.44M1.431.00 million shs684,572 shsTRDAEntrada Therapeutics$5.85-3.3%$6.79$4.93▼$16.45$234.87M-0.26438,722 shs566,335 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics+3.83%-4.80%+1.64%+32.47%+176.46%JANXJanux Therapeutics-2.48%-5.72%+4.71%+2.13%-42.06%JBIOJade Biosciences+2.34%-3.74%-8.31%-19.62%+130.54%TRDAEntrada Therapeutics-3.31%-15.09%-22.41%-53.68%-8.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics 2.86Moderate Buy$45.80148.37% UpsideJANXJanux Therapeutics 2.50Moderate Buy$38.08148.42% UpsideJBIOJade Biosciences 2.90Moderate Buy$51.57156.83% UpsideTRDAEntrada Therapeutics 2.33Hold$17.50199.15% UpsideCurrent Analyst Ratings BreakdownLatest TRDA, JANX, JBIO, and AVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2026AVTXAvalo Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight7/20/2026JANXJanux Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/6/2026AVTXAvalo Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$38.006/30/2026AVTXAvalo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/25/2026JANXJanux Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.00 ➝ $26.006/16/2026JBIOJade Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)6/16/2026AVTXAvalo Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$58.006/15/2026AVTXAvalo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/15/2026JBIOJade Biosciences UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.006/15/2026JBIOJade Biosciences UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.006/12/2026AVTXAvalo Therapeutics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.00(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$60K16,257.93N/AN/A$4.49 per share4.11JANXJanux Therapeutics$10M93.48N/AN/A$15.91 per share0.96JBIOJade BiosciencesN/AN/AN/AN/A$6.74 per shareN/ATRDAEntrada Therapeutics$25.42M8.93N/AN/A$8.01 per share0.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$78.26M-$5.46N/AN/AN/AN/A-97.54%-72.42%8/6/2026 (Estimated)JANXJanux Therapeutics-$113.62M-$1.84N/AN/AN/AN/A-12.93%-12.23%8/6/2026 (Estimated)JBIOJade Biosciences-$127.41M-$2.02N/AN/AN/AN/A-51.34%-47.32%N/ATRDAEntrada Therapeutics-$143.75M-$3.99N/AN/AN/A-2,895.05%-51.22%-42.20%8/5/2026 (Estimated)Latest TRDA, JANX, JBIO, and AVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026AVTXAvalo Therapeutics-$0.66N/AN/AN/AN/AN/A8/6/2026Q2 2026JANXJanux Therapeutics-$0.26N/AN/AN/A$19.08 millionN/A8/5/2026Q2 2026TRDAEntrada Therapeutics-$1.0493N/AN/AN/A$2.23 millionN/A5/13/2026Q1 2026AVTXAvalo Therapeutics-$1.00-$0.98+$0.02-$0.98$0.05 millionN/A5/7/2026Q1 2026JANXJanux Therapeutics-$0.5202-$0.39+$0.1302-$0.39$4.36 million$3.73 million5/7/2026Q1 2026JBIOJade Biosciences-$0.52-$0.57-$0.05-$0.57N/AN/A5/7/2026Q1 2026TRDAEntrada Therapeutics-$1.06-$0.95+$0.11-$0.95$2.92 million$0.88 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/AJBIOJade BiosciencesN/AN/AN/AN/AN/ATRDAEntrada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A7.667.66JANXJanux TherapeuticsN/A17.0117.01JBIOJade BiosciencesN/A14.2914.29TRDAEntrada TherapeuticsN/A13.9013.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%JANXJanux Therapeutics75.39%JBIOJade BiosciencesN/ATRDAEntrada Therapeutics86.39%Insider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics4.46%JANXJanux Therapeutics7.90%JBIOJade Biosciences23.06%TRDAEntrada Therapeutics9.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics4052.90 million50.54 millionNot OptionableJANXJanux Therapeutics3060.98 million56.17 millionOptionableJBIOJade Biosciences2049.36 million37.98 millionN/ATRDAEntrada Therapeutics11038.82 million35.14 millionOptionableTRDA, JANX, JBIO, and AVTX HeadlinesRecent News About These CompaniesEntrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Average Recommendation of "Hold" from BrokeragesJuly 10, 2026 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Trading 1.1% Higher - Still a Buy?July 9, 2026 | marketbeat.comOppenheimer Remains a Buy on Entrada Therapeutics Inc (TRDA)June 14, 2026 | theglobeandmail.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Pfizer (PFE)June 9, 2026 | theglobeandmail.comEntrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAJune 4, 2026 | prnewswire.comIndependent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 StudyJune 2, 2026 | markets.businessinsider.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAJune 2, 2026 | globenewswire.comIndependent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 StudyJune 2, 2026 | globenewswire.comEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | markets.businessinsider.comEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 28, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 26, 2026 | globenewswire.comBernhardt Zeiher Buys 5,000 Shares of Entrada Therapeutics (NASDAQ:TRDA) StockMay 22, 2026 | insidertrades.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 21, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 19, 2026 | globenewswire.comINVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLCMay 18, 2026 | globenewswire.comTRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the ...May 18, 2026 | caledonianrecord.comCTRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law FirmMay 17, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 14, 2026 | prnewswire.comEntrada Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesMay 11, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRDA, JANX, JBIO, and AVTX Company DescriptionsAvalo Therapeutics NASDAQ:AVTX$18.44 +0.68 (+3.83%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$18.43 -0.01 (-0.05%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Janux Therapeutics NASDAQ:JANX$15.33 -0.39 (-2.48%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$15.33 0.00 (0.00%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Jade Biosciences NASDAQ:JBIO$20.08 +0.46 (+2.34%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$20.56 +0.48 (+2.41%) As of 07/24/2026 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Entrada Therapeutics NASDAQ:TRDA$5.85 -0.20 (-3.31%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$5.85 0.00 (0.00%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Plugging In: How Kinder Morgan Powers Up Profits TSMC’s Price Hikes Could Show Which AI Chip Stocks Have Real Pricing Power AMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip Battle Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
